A potent human immunodeficiency virus type 1 protease inhibitor, UIC-94003 (TMC-126), and selection of a novel (A28S) mutation in the protease active site

Journal of Virology

Volumn 76, Issue 3, 2002, Pages 1349-1358

  Yoshimura, Kazuhisa ^a   Kato, Ryohei ^a   Kavlick, Mark F ^a   Nguyen, Aline ^a   Maroun, Victor ^a   Maeda, Kenji ^a   Hussain, Khaja A ^a   Ghosh, Arun K ^a   Gulnik, Sergei V ^a   Erickson, John W ^a   Mitsuya, Hiroaki ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 TETRAHYDROFURANYL URETHANE; ANTIVIRUS AGENT; PROTEINASE INHIBITOR; SULFONAMIDE; TMC 126; UIC 94003; UNCLASSIFIED DRUG; URETHAN DERIVATIVE;

AMINO ACID SEQUENCE; ARTICLE; ENZYME ACTIVE SITE; HUMAN IMMUNODEFICIENCY VIRUS 1; MOLECULAR MODEL; NONHUMAN; PRIORITY JOURNAL; STRAIN DIFFERENCE;

EID: 0036145503     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.76.3.1349-1358.2002     Document Type: Article

References (39)

1. Structure of HIV-1 protease with KNI-272, a tight-binding transition-state analog containing allophenylnorstatine
2. Isolation of a new human retrovirus from West African patients with AIDS
3. Genetic correlates of in vivo viral resistance to indinavir, a human immunodeficiency virus type 1 protease inhibitor
4. In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors
5. In search of a selective antiviral chemotherapy
6. Structural mechanisms of HIV drug resistance
7. Protease inhibitors: Resistance, cross-resistance, fitness and the choice of initial and salvage therapies
8. Combination therapy with amprenavir, abacavir, and efavirenz in human immunodeficiency virus (HIV)-infected patients failing a protease-inhibitor regimen: Pharmacokinetic drug interactions and antiviral activity
9. The role of mononuclear phagocytes in HTLV-III/LAV infection
10. Potent HIV protease inhibitors incorporating high-affinity P2-ligands and (R)-(hydroxyethylamino)sulfonamide isostere
11. Structure based design: Novel spirocyclic ethers as nonpeptidal P2-ligands for HIV protease inhibitors
12. Structure-based design of HIV-1 protease inhibitors: Replacement of two amides and a 10 pi-aromatic system by a fused bis-tetrahydrofuran
13. Factors associated with clinical and virological failure in patients receiving a triple therapy including a protease inhibitor
14. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy
15. HIV protease: Enzyme function and drug resistance
16. Kinetic characterization and cross-resistance patterns of HIV-1 protease mutants selected under drug pressure
17. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less
18. Active-site mobility in human immunodeficiency virus, type 1, protease as demonstrated by crystal structure of A28S mutant
19. Selection of multiple human immunodeficiency virus type 1 variants that encode viral proteases with decreased sensitivity to an inhibitor of the viral protease
20. Crystal structure of HIV-1 protease in complex with VX-478, a potent and orally bioavailable inhibitor of the enzyme
21. Application of a gastric cancer cell line (MKN-28) for anti-adenovirus screening using the MTT method
22. Discovery and development of antiretroviral therapeutics for HIV infection
23. Ordered accumulation of mutations in HIV protease confers resistance to ritonavir
24. In vitro selection and characterization of human immunodeficiency virus type 1 (HIV-1) isolates with reduced sensitivity to hydroxyethylamino sulfonamide inhibitors of HIV-1 aspartyl protease
25. Antiviral and resistance studies of AG1343, an orally bioavailable inhibitor of human immunodeficiency virus protease
26. Genotypic and phenotypic characterization of human immunodeficiency virus type 1 variants isolated from patients treated with the protease inhibitor nelfinavir
27. Rapid and automated tetrazolium-based colorimitric assay for teh detection of anti-HIV compounds
28. In vitro selection and characterization of VX-478 resistant HIV-1 variants
29. HIV-2 EHO isolate has a divergent envelope gene and induces single cell killing by apoptosis
30. Human immunodeficiency virus type 1 protease inhibitors: Evaluation of resistance engendered by amino acid substitutions in the enzyme's substrate binding site
31. Emergence of human immunodeficiency virus type 1 variants with resistance to multiple dideoxynucleosides in patients receiving therapy with dideoxynucleosides
32. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults
33. In vitro induction of human immunodeficiency virus type 1 variants resistant to 2′-β-fluoro-2′,3′-dideoxyadenosine
34. Combination of mutations in human immunodeficiency virus type 1 reverse transcriptase required for resistance to the carbocyclic nucleoside 1592U89
35. Public health implications of antiretroviral therapy and HIV drug resistance
36. Human immunodeficiency virus type 1 protease genotypes and in vitro protease inhibitor susceptibilities of isolates from individuals who were switched to other protease inhibitors after long-term saquinavir treatment
37. Outcome and predictors of failure of highly active antiretroviral therapy: One-year follow-up of a cohort of human immunodeficiency virus type 1-infected persons
38. Structure-based inhibitors of HIV-1 protease
39. JE-2147: A dipeptide protease inhibitor (PI) that potently inhibits multi-PI-resistant HIV-1